Myriad Genetics (MYGN) Change in Cash (2009 - 2026)

Myriad Genetics has disclosed Change in Cash across 18 years of filings, most recently posting -$25.3 million for Q1 2026.

• In Q1 2026, Change in Cash fell 132.11% year-over-year to -$25.3 million; the TTM figure through Mar 2026 stood at $25.0 million (up 643.48% YoY), while the FY2025 annual figure was $39.4 million, up 235.86% from the prior year.
• Change in Cash retreated to -$25.3 million in Q1 2026, from -$3.5 million in the prior quarter.
• Over the last five years, Change in Cash for MYGN reached as high as $71.1 million in Q3 2025 and fell as low as -$93.2 million in Q1 2022.
• The 5-year median for Change in Cash is -$4.4 million (2024), against an average of -$7.8 million.
• Annual changes were most pronounced in 2024 — Change in Cash plunged 969.7% — and 2025, when it jumped 726.74%.
• A 5-year view of Change in Cash shows it stood at -$44.3 million in 2022, then surged by 226.19% to $55.9 million in 2023, then plunged by 96.24% to $2.1 million in 2024, then sank by 266.67% to -$3.5 million in 2025, then tumbled by 622.86% to -$25.3 million in 2026.
• According to Business Quant data, Change in Cash over the past three periods registered -$25.3 million, -$3.5 million, and $71.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.